The company’s focus remains on the development of novel cannabinoid-based therapies for a range of diseases.
Zelda is undertaking a human clinical trial program focused on insomnia, autism and opioid reduction with activities in Australia and the US.
Pre-clinical research activities include programs examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.
Zelda also formed a strategic partnership with European medicinal cannabis group HAPA Medical BV, to access HAPA’s EU-GMP grade manufacturing capabilities and accessing its German distribution network
Proactive spoke to Zelda’s managing director Dr Richard Hopkins about their vertically integrated strategy in December 2018.